TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All women \>37 weeks gestation who desire LNG-IUS for postpartum contraception who do not have a contraindication as described below will be offered participation in our study.~Exclusion Criteria:~Contraindications to the LNG-IUS include:~* Pregnancy or suspicion of pregnancy~* Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity~* Postpartum endometritis within the past 3 months~* Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear~* untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections~* acute liver disease or liver tumor~* hypersensitivity to any component of the product~* known or suspected carcinoma of the breast~Any of these conditions would exclude the patient from receiving these forms of contraception in our study.~In addition the following intrapartum findings, the following would exclude the patient:~* Delivery \<37 weeks~* Intrapartum chorioamnionitis (defined as maternal fever \>100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid~* Postpartum Hemorrhage (defined as \>500cc EBL for spontaneous vaginal delivery or \>1000cc for cesarean delivery)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Immediate (Type: EXPERIMENTAL): LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
- Interval (Type: ACTIVE_COMPARATOR): LNG-IUS insertion after 6 weeks postpartum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acutely ill with one or more COVID-19 symptoms~Exclusion Criteria:~* Unable to speak English~* Unable to provide written informed consent~* Symptoms have lasted longer than 5 days~* Currently hospitalized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Population (Type: OTHER): All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR criteria.~* Subjects who are planned to start treatment with ADA, ETA, CER or IFX~* Subjects taking a minimum weekly dose of 7.5 mg of methotrexate~Exclusion Criteria:~* Patients with compliance problems~* Patients who have difficulties in reading and understanding local language~* Patients with Juvenile Idiopathic Arthritis (JIA)~* Azathioprine or cyclophosphamide treatment within 6 months before entering into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adalimumab (Type: None): None
- Etanercept (Type: None): None
- infliximab (Type: None): None
- Certolizumab (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mixed Music Intervention on Sleep Disturbance in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The test subjects must be adults or elderly aged 30 to 80 years old, with clear consciousness (Glasgow Coma Scale score 15), no obvious hearing impairment, diagnosed with Parkinson's disease in the first to third stages, Pittsburgh sleep quality expression is more than 5 points, has the ability to move independently with assistance,can communicate in Chinese or Taiwanese, and usually be accompanied by the main caregiver or family members.~Exclusion Criteria:~* Exclusions included skeletal injuries or medical orders that restricted or prohibited activities prior to the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- mixed music group (Type: EXPERIMENTAL): If assigned to the mixed music group, in order to synchronize active daytime music and passive music at bedtime, active daytime music will require patients to perform physical music activities once a week and watch a recorded music intervention video three times a week during the study period (The content is the same as the physical music activities) and follow the activities, and the intervention content before going to bed is the same as the intervention content of the pure passive music group.
- pure passive music group (Type: ACTIVE_COMPARATOR): If assigned to the pure passive music group, they are required to listen to soft and low-pitched music at about 60 beats per minute 30 minutes before bed every day for four weeks.
- conventional treatment (Type: NO_INTERVENTION): Conventional treatment group maintained their original lifestyle and were post-tested with the assistance of a single-blind study evaluator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib For Treatment Of Chronic Pouchitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects ages 18 to 80~2. Subjects with a history of proctocolectomy with ileal pouch anal anastomosis (IPAA) for UC at least 6 months prior to screening.~3. Subjects with pouchitis that is chronic, defined by a mPDAI score ≥5 assessed as the average from 3 days immediately prior to the baseline study visit and a minimum endoscopic sub-score of 2 (outside the staple or suture line) with either (a) ≥ 3 recurrent episodes within 1 year prior to the screening treated with ≥2 weeks of antibiotic or other prescription therapy, (b) requiring maintenance antibiotic therapy taken continuously for ≥4 weeks immediately prior to the baseline study visit~4. Women of childbearing potential must have documentation of a negative pregnancy test at screening and must agree to use two highly effective methods of birth control during the study and for at least 1 month after completion of study drug dosing.~Exclusion Criteria:~1. Subjects with IPAA surgery done for Crohn's disease (CD) or familial adenomatous polyposis (FAP) indications.~2. Subjects with primary CD of pouch, isolated or predominant cuffitis or mechanical complications of the ileal pouch.~3. Subjects with prior exposure to tofacitinib.~4. Subjects with a diverting stoma.~5. Subjects with a prior history or risk factors for venous thromboembolism.~6. Subjects with active bacterial, parasitic, fungal, mycobacterial, or viral infection.~7. Subjects with a history of latent or active tuberculosis.~8. Subjects positive for hepatitis B virus (HBV) surface antigen, hepatitis B virus core antibody with a negative hepatitis B surface antibody or with detectable serum hepatitis B DNA.~9. Female subjects who are pregnant or lactating.~10. Female subjects of childbearing potential who are sexually active and do not agree to using two highly effective methods of contraception during the study period.~11. Subjects with clinically significant laboratory abnormalities at study screening.~    * Other eligibility criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Chronic pouchitis (Type: EXPERIMENTAL): This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Utilization of AMSC to Enhance Rotator Cuff Repair - Safety and Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. males or females between 40 and 65 years of age,~2. written informed consent obtained,~3. complete unilateral rotator cuff tear on pre-operative clinical and imaging findings,~4. elected to undergo an arthroscopic repair of their rotator cuff tear,~5. agreed to wear a dedicated brace for four weeks post-operatively,~6. minimum pre-operative hemoglobin of 11.0 g/dl or more~7. pre-operative platelet count greater than 150 000 / 1 mm3~Exclusion Criteria:~1. a tear involving the subscapularis or biceps tendons,~2. a previous rotator cuff repair,~3. moderate-to-severe osteoarthritis of the glenohumeral joint,~4. loss of passive elevation in any direction when compared to the contralateral shoulder,~5. fatty infiltration greater than 50 % of the cross-sectional area of supraspinatus or infraspinatus assessed on the most lateral image on which the scapular spine is in contact with the scapular body,~6. a massive tear with a contracted immobile cuff confirmed in operation,~7. an active infection, osteomyelitis or sepsis or distant infections which may spread to the site of operation,~8. other diseases which may have limit follow-up (immunocompromising, hepatitis, active tuberculosis, neoplastic diseases, septic arthritis),~9. osteomalacia or other metabolic bone disorders which may impair bone or soft tissue function,~10. vascular insufficiency, muscular atrophy or neuromuscular diseases of the affected arm,~11. haemato/oncological diseases,~12. pregnant or lactating women,~13. alcohol or drug abusers,~14. patients on corticosteroids, immunosuppressants or anticoagulant therapy,~15. women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners,~16. fertile men not using proven contraceptive measures including effective contraception of their partners (established oral contraception, intrauterine device, ligation of the uterine tube).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Suspension of human autologous MSC 3P (Type: EXPERIMENTAL): Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Lexapro and Massage for Treatment of Depression in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \> 60 years of age~2. Unipolar major depression as defined by Structured Clinical Interaction DSM-IV (SCID)~3. HAM-D score of \> 17 (21-item scale)\]\]~4. Not taking antidepressants for at least two weeks, 2 months for fluoxetine and MAOIs\]\]~5. Capable of giving informed consent.~Exclusion Criteria:~1. Unable to provide informed consent (e.g. severe cognitive impairment)~2. Acute medical condition or exacerbation of chronic medical condition associated with significant distress (pain, protracted fevers, etc.) and requiring active medical treatment.~3. High risk of suicide or violence as assessed by the investigator~4. Current or past history of psychosis or bipolar disorder~5. Use of psychotropic medication and/or psychotherapy outside of the study~6. (Exposure to treatment of fluoxetine or MAOIs in the previous two months; chronic use of benzodiazepine and non-benzodiazepine sedatives, antipsychotics, psychostimulants, mood stabilizing agents, codeine, steroids, anti-inflammatory agents.~7. Alternative medicine use in the preceding 30 days (e.g. acupuncture, herbs, etc.)~8. History of intolerance to massage or contraindication to massage (e.g. skin lesions that prevent direct contact by the therapist)~9. Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders;~10. MMSE less than 22~11. Alzheimer's Disease Assessment Scale-Cognitive Subscale ³ greater than 12~12. Current drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months~13. Unstable medical or neurological conditions that are likely to interfere with the treatment of depression~14. Currently on psychotropic medications including antidepressants or neuroleptics~15. Active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Swedish Massage (Type: EXPERIMENTAL): Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
- Light-Touch (Type: SHAM_COMPARATOR): Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age ≥ 18~* Able to give informed consent~* Scheduled for surgery at Brigham and Women's Hospital for known or highly suspected Stage III or IV ovarian cancer (i.e. elevated CA-125 with a pelvic mass, ascites, and carcinomatosis)~* Post-menopausal or negative urine and/or blood pregnancy test~* Measurable disease on preoperative imaging~Exclusion Criteria:~* Male~* Age \< 18~* Unable to give informed consent~* Not planned for surgical intervention~* Active malignancy other than ovarian cancer~* Prior bilateral tubal ligation or hysterectomy (as this would prevent chromopertubation)~* Known or suspected active pelvic infection~* Pregnancy~* No measurable disease or suspected Stage I or II ovarian cancer on preoperative imaging

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Culdocentesis (Type: EXPERIMENTAL): * Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~* During Surgery:~  * Blood Collection~ * Vaginal Swab~ * Chromopertubation~ * Culdocentesis~ * Tissue Collection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SARS-CoV-2 OTC At Home Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals suspected of COVID-19 disease by a healthcare provider or individuals who have tested positive within the past 7 calendar days with a confirmed positive COVID-19 test~2. Individuals able to self-administer the investigational test either upon themselves or upon their child (under sixteen (16) years of age) as a parent or guardian~3. Individuals willing and able to provide informed consent or obtain consent from legal authorized representative (LAR)~Exclusion Criteria:~1. If symptomatic, individuals with self-declared symptoms greater than 7 days (plus/minus 1 day, if symptoms start not definite)~2. Unable to provide consent or obtain consent from a LAR~3. Unwilling or unable to collect all sample types~4. Enrolled in a study to evaluate an investigational drug~5. Eating/drinking/smoking 30 minutes prior to specimen collection~6. Prisoner or under incarceration~7. Have contraindications to the collection of nasal specimens from the nares/nostrils, such as but not limited to nasal ulcers or nasal surgery within 3 months prior to sample collection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study Groups (Type: EXPERIMENTAL): Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic~Each broken down by age groups:~2-14 years old 15-24 years old 25-64 years old 65+ years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Creating African-American Wellness Through Exercise

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* African-American or of African-American descent~* Currently participating in the African-American Health Coalition Free Exercise-Card Program~* Experiencing moderate depressive symptoms, as indicated by a score of 10-20 on the Depression Scale of the Patient Health Questionnaire (PHQ-9.~* Exercising less than three times per week (for a minimum of 30 minutes per session) over the past month~Exclusion Criteria:~* Actively suicidal~* If a health care provider, AAHC staff member, or an investigator feel that participation in the program may endanger the participant's health or safety.~* Known mental or cognitive impairments~* Known condition that precludes their ability to feasibly participate in a support group session.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AAHC Excercise Program Support Group (Type: EXPERIMENTAL): Participants taking part in the AAHC Exercise Program Support Group (the intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Severe Women Injury Factors Test (SWIFT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Admission to emergency for intimate partner violence~* Or consultation to SOS doctor for intimate partner violence~* Or consultation to medico-judicial unit for intimate partner violence~* No verbal opposition to inclusion~Exclusion Criteria:~* Non intimate partner violence~* Patient under guardianship or curatorship~* Non French speaker~* Coma or inability to express non-opposition~* Prior participation in another center

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women consulting for spouse abuse (Type: None): The study focuses on women consulting a doctor as part of spouse abuse, whatever the context (at the request of the police or not) or their motivation (medical or social).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-80 years of age;~* RA for \>=3 months;~* receiving outpatient treatment;~* failed treatment with \>=1 DMARD (but not anti TNF or other biologic therapy);~* inadequate response to methotrexate, having taken and tolerated it for \>=12 weeks, with a stable dose for \>=4 weeks.~Exclusion Criteria:~* rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;~* history of, or current, inflammatory joint disease other than RA, or other systemic autoimmune disorder;~* diagnosis of RA before the age of 16;~* bone/joint surgery within 12 weeks of study;~* prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues